Latest News and Press Releases

Conference Call to Begin Today at 5:00 p.m. (ET) 2021 Total Revenues of $75.4 million; +16% vs. 2020 4Q 2021 Afrezza Net Revenue of $11.3 million; +13% vs. 4Q 2020$260.7 million of Cash, Cash...

WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2021 fourth quarter and full year financial results, and its...

DANBURY, Conn., Feb. 10, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with...

DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with...

MannKind purchased an additional convertible note issued by Thirona BioNonclinical PD study of MNKD-501 planned, with results anticipated in 2Q 2022MannKind’s CEO appointed as a member of the Thirona...

WESTLAKE VILLAGE, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for...

Conference Call to Begin Today at 5:00 p.m. (ET) 3Q 2021 Total Revenues of $22.2 million; +45% vs. 3Q 20203Q 2021 Afrezza Net Revenue of $9.8 million; +34% vs. 3Q 2020$181.1 million of Cash, Cash...

WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Nov. 09, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...

A Technosphere® Insulin (TI) dose – approximately double the estimated mealtime subcutaneously (SC) injection dose – reduced postprandial glucose excursions (PPGE) without any severe hypoglycemia in...